Skip to main content
. 2024 Feb 8;12(4):440–452. doi: 10.1158/2326-6066.CIR-23-0609

Figure 1.

Figure 1. Immunogenicity of GAd adenoviral vectors encoding CT26 nAgs. A, Schematic representation of GAd adenoviral vectors: Six immunogenic nAgs (#4, #5, #11, #18, #23, #28), including both CD4 (in blue) and CD8 (in red) reactivities, selected from the previously published GAd-31 vaccine (12), were cloned to generate different GAd-6 multi-epitopes (constructs 1–4) or GAd mono-epitope vectors (constructs 5–6). WT, wild-type. B, Ex vivo IFNγ ELISpot showing Ag-specific immune responses following naïve mice immunization with the indicated GAd vaccines. Results are expressed as mean + S.E.M. of spot forming cells (SFC) per million of splenocytes (n = 6 mice/group). Positive and negative responses are indicated with + and −, respectively, according to criteria of positivity described in the Materials and Methods section. Data are representative of three independent experiments.

Immunogenicity of GAd adenoviral vectors encoding CT26 nAgs. A, Schematic representation of GAd adenoviral vectors: Six immunogenic nAgs (#4, #5, #11, #18, #23, #28), including both CD4 (in blue) and CD8 (in red) reactivities, selected from the previously published GAd-31 vaccine (12), were cloned to generate different GAd-6 multi-epitopes (constructs 1–4) or GAd mono-epitope vectors (constructs 5–6). WT, wild-type. B,Ex vivo IFNγ ELISpot showing Ag-specific immune responses following naïve mice immunization with the indicated GAd vaccines. Results are expressed as mean + S.E.M. of spot forming cells (SFC) per million of splenocytes (n = 6 mice/group). Positive and negative responses are indicated with + and −, respectively, according to criteria of positivity described in the Materials and Methods section. Data are representative of three independent experiments.